Recursion Pharmaceuticals Inc (RXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.10 Million) by net assets ($1.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Recursion Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Recursion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Recursion Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Recursion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
-0.103x |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
0.069x |
|
Lotte Chemical Corp
KO:011170
|
-0.034x |
|
Gas Malaysia Bhd
KLSE:5209
|
0.049x |
|
SVG Optronics Co Ltd
SHE:300331
|
0.030x |
|
nCino Inc
NASDAQ:NCNO
|
0.083x |
|
Hankook Tire Worldwide
KO:000240
|
0.016x |
|
S&T Bancorp Inc
NASDAQ:STBA
|
0.026x |
Annual Cash Flow Conversion Efficiency for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Recursion Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.13 Billion | $-371.81 Million | -0.329x | +5.28% |
| 2024-12-31 | $1.03 Billion | $-359.17 Million | -0.347x | +44.10% |
| 2023-12-31 | $463.44 Million | $-287.78 Million | -0.621x | -261.18% |
| 2022-12-31 | $485.81 Million | $-83.52 Million | -0.172x | +41.15% |
| 2021-12-31 | $542.94 Million | $-158.61 Million | -0.292x | -232.75% |
| 2020-12-31 | $-206.29 Million | $-45.40 Million | 0.220x | -52.06% |
| 2019-12-31 | $-124.27 Million | $-57.04 Million | 0.459x | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more